Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.
Don’t miss the WestWind podcast with Dr. Jack West hosting Dr. Addeo to learn more about his path and challenges from Italy over UK to Switzerland.
He was trained and received his doctorate in Italy from the University School of Medicine in Turin. After his residency, he worked for another 4 years in Turin as a Consultant Oncologist. From 2010 to 2017 he further sharpened his interest in thoracic malignancies in the UK. First at the United Lincolnshire Hospital NHS Trust and later at the University Hospital Bristol, Dr. Addeo also took on the role as senior lecturer in Medical Oncology. As an active member of the NCRI Mesothelioma Working Group, he has also participated in several national and international NCRI drug studies. Dr. Addeo’s research continues to focus on drug development and translational aspects of precision medicine, immunotherapy and side effects, particularly in small and non-smal cell lung cancer (NSCLC) as well as melanoma.
During his time in the UK, Dr. Addeo developed further research interests in liquid biopsies, ctDNA analysis, and tumor mutation burden (TMB) in blood samples. For his research activities in this field he received a grant for a research proposal, which is still ongoing.
In September 2017, Dr. Addeo moved to Geneva, where he received the post of medical oncologist with a primary responsibility for Thoracic Malignancies.
Solange Peters, MD, PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at the University Hospital of Lausanne, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President-elect ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.
Professor Peters is currently in charge of teaching and patient care in the area of Thoracic Malignancies in the department of oncology of Lausanne University, where she is building a translational programme in collaboration with the molecular oncology laboratory directed by Dr. Hanahan at the Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute. Professor Peters’ main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy.
Professor Peters’ current research projects are focused on multimodality stage III NSCLC treatment strategies, immunotherapy in limited small cell lung cancer and advanced thymic malignancies, advanced NSCLC, ALK inhibitors, HER2 inhibitors, as well as immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre, focused on phase I predictive biomarkers and thoracic malignancies immunotherapy, and is a co-PI of several other trials. Additionally, she acts as the scientific coordinator of the European Thoracic Oncology Platform (ETOP).
|(Central European Time)|
|13.00||Welcome & introduction||S. Peters &
|13.10||The power of social media in Oncology: what we can learn from our virtual peers||G. Morgan|
|13.30||Treatment standards in non-oncogene addicted NSCLC before COVID19||M. Pérol|
|13.50||How can we treat patients with lung cancer during the SARS-CoV-2 pandemic||G. Banna|
|14.10||COVID19 & lung cancer: treatment & outcomes from a Spanish cohort||A. Calles|
|14.30||Radiotherapy in lung cancer during the COVID-19 era||A. Durham|
|14.50||Mesothelioma: new therapeutic strategies and future perspectives for a difficult disease with a heavy social burden||A. Curioni|
|15.40||Small cell lung cancer (SCLC): Treatment challenges and a glimpse into the development of new targets||S. Liu|
|16.00||Personalized Medicine with IO: can we tailor immunotherapy options to patients?||J. Bauml|
|16.20||Actionable mutations on the horizon: up and coming agents in targeted therapies||C. Rolfo|
|16.40||Tailoring targeted therapies: what TKI is suitable for what patient?||H. West|
|17.00||Integrating immunotherapy into localized NSCLC||S. Patel|
|17.20||Final Questions and Wrap Up||A. Addeo & S. Peters|
International Lung Cancer SummitFollow
Leading MedOncs in Thoracic Cancer discuss recent discoveries & advances for the treatment of lung cancer at the ILCS. Register @ https://t.co/0ixI9mMVzl
In the wake of #ADAURA trial, what will your practice be for molecular testing in patients with resected stage IB-IIIA NSCLC?
Please amplify as needed in the comments.
@VPrasadMDMPH @FAndreMD Let me echo you in thanking @FAndreMD and @Annals_Oncology for hosting the debate .
@VPrasadMDMPH @VivekSubbiah @DSolit @GeneCollector @Dr_R_Kurzrock It has been a pleasure. Thanks to you @VPrasadMDMPH for letting me be part of this. Thanks to @VivekSubbiah @DSolit @GeneCollector @Dr_R_Kurzrock for their thoughtful arguments. Life would be more boring if we all agreed on everything.
Good news for ALK patients: Lorlatinib Significantly Improves PFS vs crizotinib in untreated #ALK #NSCLC. This is only the Press release. Looking forward to seeing the numbers and to compare with Alectinib in ALEX. @OncoAlert #LCSM https://www.businesswire.com/news/home/20200805005244/en/LORBRENA%C2%AE-lorlatinib-Significantly-Improves-Progression-Free-Survival-First-Line
Your pt w/adv EGFR mut+ NSCLC responded on 1L osimertinib x21 mos, now multifocal PD in chest & new liver mets. Repeat Bx shows orig EGFR mut'n, no new target. No trial available, so you decide to transition to chemo. No h/o brain mets.
Continue osi if can get it covered?
Attention fellows and trainees - I know there's been fewer educational opportunities due to #COVID19. I am doing a webinar on lung cancer on August 11 at 6 PM EST with @CCO_Oncology. Would love to have as many trainees that are interested register here https://wendyballard.my.webex.com/wendyballard.my/j.php?RGID=rab348d35e2080cbc576ac5c3b93fb0f4
Edward B. Garon, MD, of @UCLAHealth, on next steps with PD-1/PD-L1 inhibition and anti–CTLA-4 agents in NSCLC. #lcsm http://ow.ly/Ujgj50AWVD2
“How can patients prepare to continue w/ lung ca therapy during the pandemic?”
I sat down with @LUNGevity to answer common questions and discuss measures we’re taking @PennCancer to ensure *safe* delivery of cancer care during the #COVID19 pandemic.
#LCSM @PennMedNews https://twitter.com/LUNGevity/status/1293200681063636993
LUNGevity spoke with @CharuAggarwalMD, a leading researcher & thoracic medical oncologist with @PennCancer’s Abramson Cancer Center. Hear detailed thinking on how to access #lungcancer care during the #COVID19 pandemic. Watch the full interview here: https://bit.ly/2PKpd1D #LCSM
#OncoAlert Nice case report @JTOonline #JTOCRR by @nicogirardcurie reporting acquired METex14 mutation mediating early resistance (at 1y) to alectinib in #ALK NSCLC. Responded to crizotinib until a different MET mutation emerged. #NGS #LCSM @IASLC
When Dening Day, mom of PGA golf champion Jason Day, found out she had #lungcancer, she had questions and they were determined to find answers. Learn how getting a complete diagnosis helped them find a treatment right for her type of lung cancer. #LCSM
We advocate for the future of #LungCancer . My wish is for #LungCancer is #IncreasedAwareness , #Earlydiagnosis, #Screeningprograms, #Morefunding, #MoreResearch , #MoreSurvivors. This is why I advocate #GiveLungCancerAVoice #LungCancerStrong #LCSM
#LungCancer Ottawa Support Group completed the 2K . Help us raise money for @LungCancer_Can. We are #LungCancerStrong #LoveLungSparkle
Tamarack Ottawa Virtual Race Weekend 2020 #LCSM #ResearchMatters https://raceroster.com/events/2020/24011/tamarack-ottawa-virtual-race-weekend-2020/pledge/participant/9166623……… via
For sponsoring requests, please contact us at firstname.lastname@example.org